Glucose Dependency in JAK2V617F MPN
The study provides a mechanistic rationale to investigate the HIF-1–GLUT1/3 pathway in JAK2V617F-positive MPN, but its mixed in vivo findings mean it is not evidence for a clinically effective treatment.
> Research explainer: This briefing examines verified primary research published 59 days before the briefing date. It is not a same-day research update and does not provide medical advice.
Evidence
Myeloproliferative neoplasms (MPN) include polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The supplied source describes these disorders as clonal hematologic malignancies and focuses on the JAK2V617F driver mutation, which it identifies as present in 90% of polycythemia vera cases and in 50–60% of essential thrombocythemia or primary myelofibrosis cases (pmid:42337564).
The study tested whether altered glucose use creates a selective weakness in JAK2V617F-positive cells. Its experimental program included engineered murine 32D cell models, JAK2V617F-mutated human SET-2 and HEL cell lines, patient-derived peripheral-blood mononuclear cells, and a Jak2V617F knock-in mouse model (pmid:42337564). This mix of models allowed the authors to connect a molecular mechanism with cell-fitness assays and pharmacologic experiments, but it did not include a clinical trial.
In the engineered models, JAK2V617F induced HIF-1-dependent metabolic reprogramming, with increased glycolytic flux and oxidative metabolism (pmid:42337564). HIF-1 inhibition or Hif1α knockdown reduced expression of glycolysis-associated factors reported in the source, including GLUT1, GLUT3, and PFKFB3 (pmid:42337564). The central question was therefore not simply whether the mutant cells metabolize glucose differently, but whether that altered state depends on a tractable glucose-transport bottleneck.
The genetic experiments point to redundancy between two transporters. Complete abrogation of glucose uptake in JAK2V617F cells occurred only after combined loss of GLUT1 and GLUT3, encoded by Slc2a1 and Slc2a3, respectively (pmid:42337564). Loss of either transporter alone was therefore insufficient to eliminate glucose uptake in that model. This result supports the authors’ interpretation that the two transporters can functionally compensate for one another while sustaining the enhanced glycolytic state.
When glucose uptake was disrupted, the effect was selective in the reported JAK2V617F cell experiments: stress-associated transcriptional programs and replication stress were induced, followed by S-phase arrest, apoptosis, and reduced viability (pmid:42337564). Pharmacologic GLUT1/3 inhibition also reduced viability in SET-2 and HEL cells, both human JAK2V617F-mutated cell lines (pmid:42337564). In patient-derived peripheral-blood mononuclear cells, GLUT inhibition impaired proliferation, viability, and colony formation (pmid:42337564).
The mouse results qualify the translational interpretation. In the Jak2V617F knock-in model, pharmacologic HIF-1 or GLUT inhibition reorganized erythropoiesis toward the spleen but did not ameliorate core disease features (pmid:42337564). Thus, the source reports a biological response in vivo without a corresponding improvement in the central disease outcomes evaluated in that model.
Analysis — Glucose Transport Dependency
The study’s strongest contribution is its mechanistic chain: JAK2V617F is linked to HIF-1-dependent metabolic reprogramming; glucose uptake depends jointly on GLUT1 and GLUT3 in the engineered mutant cells; and interruption of that uptake produces replication stress, cell-cycle disruption, apoptosis, and lower viability in the reported in vitro systems (pmid:42337564). That chain makes the HIF-1–GLUT1/3 axis a plausible research target rather than merely an observed metabolic correlate. The combined knockout result is particularly important because it argues against interpreting either transporter in isolation as the full dependency.
The translational signal is uneven. Human mutant cell lines and patient-derived peripheral-blood mononuclear cells showed reduced fitness after GLUT inhibition, but the mouse interventions did not improve core disease features (pmid:42337564). The evidence therefore supports further investigation of pathway inhibition and does not establish disease modification, malignant-clone eradication, clinical benefit, or acceptable safety in people. The work is best read as a preclinical explanation of why glucose transport may be worth testing in JAK2V617F-positive MPN models, alongside a clear reminder that cellular selectivity and in vivo therapeutic benefit are separate evidentiary thresholds.
Limitations
This is a preclinical study spanning engineered cells, human cell lines, patient-derived cells, and a mouse model; it does not demonstrate efficacy or safety in patients (pmid:42337564). The reported therapeutic effects were principally observed in vitro, whereas HIF-1 or GLUT inhibition in the cited knock-in mouse model did not ameliorate core disease features (pmid:42337564). The direct evidence concerns JAK2V617F-positive models, so it should not be generalized to MPN driven by CALR or MPL mutations, or to all people with MPN, without additional evidence (pmid:42337564). Finally, the authors describe a rationale for further investigation of HIF-1 or GLUT inhibitors; the source does not validate a treatment, support patient-specific conclusions, or show that malignant clones can be eradicated in patients (pmid:42337564).